NADAC acquisition cost data for ESTRADIOL-NORETH 1-0.5 MG TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00378729553 | $0.7964 | 2022-12-21 | Rx |
| 00378729585 | $0.7964 | 2022-12-21 | Rx |
| 50742065728 | $0.7964 | 2022-12-21 | Rx |
| 50742065784 | $0.7964 | 2022-12-21 | Rx |
| 51991047428 | $0.7964 | 2022-12-21 | Rx |
| 00378729553 | $0.7964 | 2022-12-21 | Rx |
| 00378729585 | $0.7964 | 2022-12-21 | Rx |
| 50742065728 | $0.7964 | 2022-12-21 | Rx |
| 50742065784 | $0.7964 | 2022-12-21 | Rx |
| 51991047428 | $0.7964 | 2022-12-21 | Rx |
Generic: Estradiol/Norethindrone Acet | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $5.3M | 40,789 | 10,085 | $2.60 |
| 2020 | $5.6M | 41,058 | 10,313 | $2.55 |
| 2021 | $5.9M | 44,147 | 11,433 | $2.37 |
| 2022 | $5.9M | 45,683 | 12,007 | $2.19 |
| 2023 | $5.4M | 46,519 | 12,551 | $1.91 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $654.4K | 5,450 | 1,494 |
| Texas | $472.0K | 4,294 | 1,200 |
| Florida | $386.7K | 3,525 | 1,022 |
| Alabama | $344.1K | 2,482 | 649 |
| New York | $278.0K | 2,277 | 594 |
| Michigan | $246.9K | 1,782 | 486 |
| Ohio | $231.0K | 1,764 | 465 |
| North Carolina | $186.4K | 1,612 | 441 |
| Virginia | $163.9K | 1,416 | 402 |
| Georgia | $152.3K | 1,464 | 424 |
| Pennsylvania | $148.7K | 1,024 | 292 |
| Illinois | $146.0K | 1,232 | 342 |
| Louisiana | $127.2K | 1,526 | 328 |
| Oklahoma | $125.4K | 993 | 261 |
| South Carolina | $118.2K | 1,159 | 332 |
| Tennessee | $117.1K | 1,183 | 318 |
| Kentucky | $109.8K | 1,037 | 229 |
| Indiana | $80.9K | 632 | 181 |
| Missouri | $80.6K | 732 | 226 |
| New Jersey | $80.1K | 645 | 191 |
| Arkansas | $74.8K | 885 | 179 |
| Arizona | $74.0K | 695 | 214 |
| Maryland | $73.0K | 517 | 170 |
| Oregon | $71.5K | 695 | 208 |
| Connecticut | $68.1K | 523 | 157 |
| Washington | $65.8K | 654 | 196 |
| Colorado | $58.4K | 507 | 154 |
| Mississippi | $52.5K | 646 | 133 |
| Kansas | $47.5K | 487 | 115 |
| Minnesota | $47.4K | 317 | 96 |
| Wisconsin | $46.2K | 331 | 106 |
| Massachusetts | $44.4K | 452 | 129 |
| West Virginia | $40.1K | 381 | 91 |
| Utah | $36.8K | 372 | 118 |
| Nevada | $33.8K | 320 | 97 |
| Nebraska | $27.9K | 320 | 83 |
| New Mexico | $27.1K | 226 | 64 |
| Montana | $24.3K | 252 | 52 |
| Idaho | $23.5K | 246 | 82 |
| Iowa | $23.1K | 215 | 55 |
| Puerto Rico | $22.3K | 263 | 47 |
| Maine | $17.3K | 133 | 44 |
| Hawaii | $16.4K | 91 | 30 |
| Rhode Island | $15.4K | 109 | 29 |
| Delaware | $15.0K | 95 | 29 |
| Wyoming | $12.7K | 107 | 26 |
| New Hampshire | $11.9K | 126 | 37 |
| District of Columbia | $11.8K | 80 | 28 |
| Alaska | $11.7K | 73 | 23 |
| Vermont | $6.0K | 54 | 19 |
| North Dakota | $5.9K | 46 | 17 |
| South Dakota | $5.2K | 39 | 13 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.